Physician profile
Sean Branch
NPI 1124333232
$201,033.17
in general payments reported to CMS, 2019-2025
28 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $11K · 2021: $12K · 2022: $21K · 2023: $33K · 2024: $43K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Travel and Lodging: $8,327 · Food and Beverage: $6,623 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,031.25 |
| Travel and Lodging | $8,327.45 |
| Food and Beverage | $6,623.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65,817.76 | 2019-2024 | |
| Galderma Laboratories, L.P. | $49,745.63 | 2019-2025 | Nemluvio, Dysport |
| Abbvie INC. | $33,807.72 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $30,161.00 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $17,058.47 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,435.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $462.30 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $379.21 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $354.35 | 2019-2025 | |
| Amgen INC. | $327.99 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $292.17 | 2019-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $203.37 | 2019-2025 | |
| Janssen Biotech, INC. | $179.64 | 2019-2024 | Tremfya |
| Almirall LLC | $149.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $137.37 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $120.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.86 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $60.10 | 2019 | |
| Journey Medical Corporation | $42.01 | 2021 | |
| Arcutis Biotherapeutics, INC. | $35.85 | 2024-2025 | Zoryve |
| Merz North America, INC. | $33.88 | 2023 | |
| Dermavant Sciences, INC. | $26.65 | 2022-2024 | Vtama |
| Organogenesis INC. | $23.03 | 2021 | |
| Celgene Corporation | $18.94 | 2019 | |
| Genentech USA, INC. | $18.65 | 2024 | Xolair |
| Dusa Pharmaceuticals, INC. | $14.70 | 2019 | |
| Organon LLC | $14.37 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.